

Bilateral Workshop

"Building a bridge between Italian and Polish Pharmaceutical Industry"

15 lutego 2022, Warszawa

Program

11:00 AM	Welcome Speeches
	Aldo Amati - Ambassador of Italy to Poland
	Radosław Sierpiński - President of the Medical Research Agency
11:10 AM	Presentation of State Support Instruments for the Development of Pharmaceutical Industries
	Radosław Sierpiński - President of the Medical Research Agency
	Giovanni Tria - Economic Advisor to the Italian Minister of Economic Development for the pharmaceutical and biotechnological sector
	Marlena Tryka - Deputy Director - Department of Innovation and Industrial Policy Ministry of Economic Development and Technology
11:40 AM	Panel Debate - Challenges of the Development of EU Pharmaceutical Industry
	<u>Sergio Dompé</u> - Chair B20 Italy - Health & Life Sciences Task Force
	Pierluigi Petrone, Member of the Chairman's Committee - Farmindustria
	Paolo Russolo - President - Aschimfarma - Federchimica
	Grzegorz Rychwalski - Vice President of the Medicines for Poland
	 <u>Piotr Rudzki</u> - President of the Board for Cooperation with Economic Environment - Committee on Therapeutics and Pharmaceutical Sciences of the Polish Academy of Sciences.
	Marcin Czech - President of the Polish Pharmacoeconomic Society (ISPOR Poland Chapter)
12:45 PM	Signing of the cooperation Agreement between the Medical Research Agency and the Angelini Pharma within the framework of the Warsaw Health Innovation Hub
12:55 PM	Networking session with buffet lunch
	The event will be conducted by:
	Piotr Żakowiecki – Senior Healthcare Analyst – Polityka Insight





Warsaw - On Tuesday, February 15, 2022, the workshop "Building a Bridge between Italian and Polish Pharmaceutical Industry" was held at the Raffles Europejski hotel in Warsaw from 10:30 to 14:00, a promotional initiative aimed at developing the collaboration Italian-Polish in the pharmaceutical sector, co-organized by the ICE-Agency Office in Warsaw and the local Embassy of Italy, in collaboration with the Polish Ministry of Development and Technology and Medical Research Agency (ABM - Agencja Badań Medycznych) Polish government agency responsible for the development of scientific research in the medical and health fields.

The event, moderated by journalist Piotr Zakowiecki (senior health policy and health sector analyst for the Polish magazine Polityka Insight), was opened by introductory speeches by the Italian Ambassador to Poland H.E. Aldo Amati and the president of the Polish agency ABM Mr. Radosław Sierpiński.

In the first part of the workshop, dedicated to the presentation of government tools to support the development of the pharmaceutical industries of the two countries, the former Italian minister Mr. Giovanni Tria, currently economic advisor to the Italian Ministry of Economic Development for the pharmaceutical and biotechnology sector, spoke in a video conference from Italy. While for the Polish part the speakers Mr. Radosław Sierpiński (president of the ABM agency) and Ms Marlena Tryka (deputy director of the innovation and industrial policy department of the Ministry of Development and Technology).

The program continued with the discussion panel on the theme "Challenges of the Development of the EU Pharmaceutical Industry" to which the speakers Mr. Sergio Dompè (Chair B20 Italy - Health & Life Sciences Task Force of Confindustria and president of the pharmaceutical group Dompé), Mr. Pierluigi Petrone (member of the Presidency Committee of Farmindustria) and Mr. Paolo Russolo (president of Aschimfarma - Federchimica) spoke online from Italy. the Polish speakers Mr. Grzegorz Rychwalski (vice president of Medicines for Poland - PZPPF - association of Polish manufacturers of generics and biosimilars), Mr. Piotr Rudzki (President of the Council for Cooperation with the Economic Environment - Committee for Therapeutic and Pharmaceutical Sciences - of the Polish Academy of Sciences) and Mr. Marcin Czech (president of the Polish Society of Pharmaceutical Economy - ISPOR Poland Chapter) took part in the debate directly on the spot in Warsaw.

At the end of the discussion panel, the representatives of the Italian company Angelini Pharma and the Polish Medical Research Agency ABM signed a cooperation agreement within the government project "Warsaw Health Innovation Hub", the first initiative of its kind in Central Europe of public-private partnership aimed at developing innovative medical, technological and legal solutions to improve patient health and increase the efficiency of the Polish health system.

Finally, the director of the ITA - Italian Trade Agency in Warsaw, Mr. Paolo Lemma, took the role and announced that a follow-up initiative focusing on the biomedical sector will soon be organized. He then closed the workshop and invited the representatives of the companies present in the room (including the Italian companies Angelini Pharma, Bracco Imaging, Chiesi, Berlin-Chemie Menarini and Kedrion Biopharma, as well as the Polish Adamed, Biofarm, Biomed Lublin, Lekam, Polfarmex and Polpharma) to start networking activities.

The Polish pharmaceutical and biomedical market has seen important developments in recent years, both in terms of turnover and investments, currently being the largest market in Central Europe and the sixth largest in the European Union. The national pharmaceutical industry alone generates a value of 7.3 billion euros, equal to 1.33% of the Polish GDP. 49% of companies are involved in innovative projects and 3.1% of all nationwide spending on innovation comes from this sector.

The Italian pharmaceutical industry is one of the most technologically advanced and important sectors in the European industrial landscape. The production value of the pharmaceutical industry in Italy in 2020 is over 34 billion euros, at the top of the European Union, with France and Germany. In the last five years, exports have registered an increase of 14 billion euros (+ 74%). Pharmaceutical companies with Italian capital make more than 70% of their sales abroad. The major trading partners are the EU countries, including Poland, which account for more than 50% of exports and almost 70% of imports.

Registration of Event